MYDX - MyDx, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0038
+0.0003 (+8.57%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.0035
Open0.0039
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0032 - 0.0040
52 Week Range0.0030 - 0.0110
Volume8,177,270
Avg. Volume10,795,374
Market Cap13.87M
Beta-3.37
PE Ratio (TTM)N/A
EPS (TTM)-0.0130
Earnings DateNov 24, 2017 - Nov 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    MyDx Announces 2018 First Quarter Results

    SAN DIEGO, CA, May 22, 2018 (GLOBE NEWSWIRE) --  MyDx, Inc.(OTC: MYDX), a leader in science based cannabis health technologies and creator of the industry’s first handheld analyzer to help consumers and professionals understand how cannabis makes cannabis users feel,today announces its 2018 first quarter earnings results and management analysis. Operations continue to be streamlined to maximize operational efficiency and minimize waste.  Gross profits remained relatively even from the same quarter in the previous year as gross margins increased by 6 percentage points. MyDx continues to deliver on its long-term growth strategy as it utilizes its database of over 10 million pre-clinical data points that tie cannabis chemical profiles to their net physiological effects. MyDx360TMis a fully integrated suite of services designed to provide brands immediate access to the legal cannabis market with differentiated products that are created using the latest science and technology.

  • MyDx Secures City and State Legal Cannabis Manufacturing and Distribution for Its MyDx360 Customers
    GlobeNewswire17 days ago

    MyDx Secures City and State Legal Cannabis Manufacturing and Distribution for Its MyDx360 Customers

    MyDx, Inc. (MYDX) (“MyDx” or the “Company”), a leader in science based cannabis health technologies and creator of the industry’s first handheld, multi-use chemical analyzer to help consumers and professionals understand how cannabis makes cannabis users feel, announced today it is excited to launch its first MyDx360 customers into the California legal cannabis market.

  • GlobeNewswirelast month

    Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran, Joins MyDx Executive Advisory Board

    MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to understand the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that Heiner Dreismann, Ph.D., has joined as the company’s Chairman of the Executive Advisory Board.  Under Dr. Dreismann’s leadership as Chief Executive Officer of Roche Molecular Systems, Roche became the global leader in molecular diagnostics by a significant expansion of their portfolio of molecular tests and respective instrumentation. Prior to his appointment as Chief Executive Officer of Roche Molecular Systems, Dr. Dreismann held several other senior positions within Roche, including head of Global Business Development for Roche Diagnostics, Business Unit Europe Manager for PCR, head of Business Unit for Microbiology, as well as R&D positions in microbiology and infectious diseases and the head of manufacturing for infectious disease diagnostics.

  • GlobeNewswirelast month

    Mydx Announces 2017 Fiscal Year Results

    MyDx, Inc. (OTC: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announces its 2017 fiscal year earnings results and management analysis.

  • The Biggest Lie In Cannabis
    PR Newswire3 months ago

    The Biggest Lie In Cannabis

    MyDx entered into an agreement to provide a licensor with access to its dataset in order to come up with a "Counterfeit Index" that determines the likelihood that a strain name doesn't tie to its chemical profile. The counterfeit index will identify and rank the strain names that have the greatest deviation in chemical profile which is often the result of intentionally mislabeling strains with names that gain extreme popularity in order to yield a greater price per gram. Since popular names yield higher prices, the index plans to inform consumers to demand confirmation of the chemical profile to ensure they're getting what they paid for.

  • The Biggest Lie In Cannabis
    CNW Group3 months ago

    The Biggest Lie In Cannabis

    MyDx entered into an agreement to provide a licensor with access to its dataset in order to come up with a "Counterfeit Index" that determines the likelihood that a strain name doesn't tie to its chemical profile. The counterfeit index will identify and rank the strain names that have the greatest deviation in chemical profile which is often the result of intentionally mislabeling strains with names that gain extreme popularity in order to yield a greater price per gram. Since popular names yield higher prices, the index plans to inform consumers to demand confirmation of the chemical profile to ensure they're getting what they paid for.

  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    PR Newswire4 months ago

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    Partnering with the Leading Israeli Research and Development Organizations and Hospitals Devoted to the Scientific Study of Cannabis SAN DIEGO , Jan. 16, 2018 /PRNewswire/ --  MyDx, Inc.  (OTCQB: MYDX), ...

  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    CNW Group4 months ago

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    SAN DIEGO , Jan. 16, 2018 /CNW/ --  MyDx, Inc.  (OTCQB: MYDX), a science and technology company and creator of MyDx ® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis ...

  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    PR Newswire4 months ago

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    SAN DIEGO, Jan. 16, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to understand the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced a definitive agreement and statement of work with a contract research organization to commence clinical trials in Israel on its proprietary pain management formula that was derived from 50,000+ pre-clinical, crowd-sourced physiological data-points tracked by MyDx's Handheld Cannabis Tester and associated mobile app.

  • MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer
    PR Newswire4 months ago

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    Board Certified Internal Medicine Doctor to Lead MyDx Clinical Research Initiatives and Support MyDx360 Formulations Services SAN DIEGO , Jan. 11, 2018 /PRNewswire/ --  MyDx, Inc. (OTC: MYDX), a science ...

  • MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer
    CNW Group4 months ago

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    SAN DIEGO , Jan. 11, 2018 /CNW/ --  MyDx, Inc. (OTC: MYDX), a science and technology company and creator of MyDx ® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis ...

  • PR Newswire4 months ago

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    SAN DIEGO, Jan. 11, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has recruited Dr. Jessica Peatross (Dr. Jess) as its Chief Medical Officer. Dr. Jess will lead the Clinical Research Initiatives that MyDx expects to begin soon as well as support formulation services offered to MyDx360 Customers. Dr. Jessica Peatross is a western trained, board certified medical doctor and Gerson Therapy practitioner who began her journey into healing in 2009 when she graduated from the University of Louisville (KY) Internal Medicine residency program.

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    PR Newswire5 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has agreed on terms and entered into a Letter of Intent to partner with Highsmen Genetics to form a new Exclusive Joint Venture. The technology behind Highsmen to develop stable customized genetic strains for certain effects is expected to help MYDX360 customers realize additional brand loyalty through end-user input in the MyDx App that will now influence the flower breeding programs that power the product lines they are consuming.

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    PR Newswire5 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has agreed on terms and entered into a Letter of Intent to partner with Highsmen Genetics to form a new Exclusive Joint Venture. The technology behind Highsmen to develop stable customized genetic strains for certain effects is expected to help MYDX360 customers realize additional brand loyalty through end-user input in the MyDx App that will now influence the flower breeding programs that power the product lines they are consuming.

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    CNW Group5 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    SAN DIEGO, Jan. 4, 2018 /CNW/ -- MyDx, Inc. (OTC:MYDX - News), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has agreed on terms and entered into a Letter of Intent to partner with Highsmen Genetics to form a new Exclusive Joint Venture. The technology behind Highsmen to develop stable customized genetic strains for certain effects is expected to help MYDX360 customers realize additional brand loyalty through end-user input in the MyDx App that will now influence the flower breeding programs that power the product lines they are consuming.

  • CNW Group5 months ago

    MyDx Cancels Reverse Stock Split

    SAN DIEGO, Dec. 20, 2017 /CNW/ -- MyDx, Inc. (OTC:MYDX - News), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that based upon recent and anticipated developments for the Company, the board has decided to cancel its plans for the reverse stock split approved earlier this year. "With the influx of interest for our MyDx360 services, including ancillary products such as the EcoSmartPenTM, as well as the progress we have made in the analysis of our 55K+ data points and the development of MyDx crowdsourced formulations, we are very optimistic about where the Company is headed into 2018.

  • MyDx Cancels Reverse Stock Split
    PR Newswire5 months ago

    MyDx Cancels Reverse Stock Split

    SAN DIEGO, Dec. 20, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that based upon recent and anticipated developments for the Company, the board has decided to cancel its plans for the reverse stock split approved earlier this year. "With the influx of interest for our MyDx360 services, including ancillary products such as the EcoSmartPenTM, as well as the progress we have made in the analysis of our 55K+ data points and the development of MyDx crowdsourced formulations, we are very optimistic about where the Company is headed into 2018.

  • MyDx Cancels Reverse Stock Split
    PR Newswire5 months ago

    MyDx Cancels Reverse Stock Split

    SAN DIEGO, Dec. 20, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that based upon recent and anticipated developments for the Company, the board has decided to cancel its plans for the reverse stock split approved earlier this year. "With the influx of interest for our MyDx360 services, including ancillary products such as the EcoSmartPen™, as well as the progress we have made in the analysis of our 55K+ data points and the development of MyDx crowdsourced formulations, we are very optimistic about where the Company is headed into 2018.

  • MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen
    PR Newswire5 months ago

    MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen

    SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it submitted an application and is seeking medical device designation in Canada for its CannaDxTM Handheld Tester and its ECOSmartPenTM in order to make its products more accessible to medicinal users seeking to track and manage their consumption habits and prevent abuse.

  • PR Newswire5 months ago

    MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen

    SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it submitted an application and is seeking medical device designation in Canada for its CannaDx™ Handheld Tester and its ECOSmartPen™ in order to make its products more accessible to medicinal users seeking to track and manage their consumption habits and prevent abuse.

  • CNW Group5 months ago

    MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen

    SAN DIEGO, Dec. 14, 2017 /CNW/ -- MyDx, Inc. (OTC:MYDX - News), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it submitted an application and is seeking medical device designation in Canada for its CannaDxTM Handheld Tester and its ECOSmartPenTM in order to make its products more accessible to medicinal users seeking to track and manage their consumption habits and prevent abuse. According to the Institute of Health Economics, under the Food and Drugs Act, medical devices have a broad definition that includes any item sold to diagnose, treat, mitigate, or prevent a disease, disorder or abnormal physical state, or any of their symptoms.

  • MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen(TM)
    PR Newswire6 months ago

    MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen(TM)

    SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it filed patents on its revolutionary, second smart device -- The ECOSmartPenTM -- and is now accepting Pre-Orders. The ECO Smart PenTM by MyDx is a next generation, rechargeable delivery pen with Bluetooth technology capable of monitoring dosages and consumer feedback. The ECO Smart Pen also comes equipped with remote access and child safety protection via the EcoSmartPen App and is designed to help patients and consumers better manage and regulate their cannabis consumption habits, while protecting their children from unsupervised use.

  • PR Newswire6 months ago

    MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen™

    SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it filed patents on its revolutionary, second smart device – The ECOSmartPenTM – and is now accepting Pre-Orders. The ECO Smart PenTM by MyDx is a next generation, rechargeable delivery pen with Bluetooth technology capable of monitoring dosages and consumer feedback. The ECO Smart Pen also comes equipped with remote access and child safety protection via the EcoSmartPen App and is designed to help patients and consumers better manage and regulate their cannabis consumption habits, while protecting their children from unsupervised use.

  • CNW Group6 months ago

    MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen™

    SAN DIEGO, Nov. 28, 2017 /CNW/ -- MyDx, Inc. (OTC:MYDX - News), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it filed patents on its revolutionary, second smart device – The ECOSmartPenTM – and is now accepting Pre-Orders. The ECO Smart PenTM by MyDx is a next generation, rechargeable delivery pen with Bluetooth technology capable of monitoring dosages and consumer feedback. The ECO Smart Pen also comes equipped with remote access and child safety protection via the EcoSmartPen App and is designed to help patients and consumers better manage and regulate their cannabis consumption habits, while protecting their children from unsupervised use.

  • MyDx Provides Corporate Update & Launches New Website
    PR Newswire7 months ago

    MyDx Provides Corporate Update & Launches New Website

    SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced the launch of its new website, www.mydxlife.com, a reimagining of its brand with greater clarification of its products and services. The structure of the new site aligns with MyDx's re-organized business segments and is set up for new customers to explore and purchase products from each of those new segments, seamlessly.